Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis
- Conditions
- Kidney Calculi
- Registration Number
- NCT01329042
- Lead Sponsor
- Ouiheng International Healthcare Co., Ltd
- Brief Summary
Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become the therapy of choice for renal stone. Although providing good results, stone recurrence is usually found as the therapies do not change the underlying metabolic abnormality. Among the metabolic disorders, hypocitraturia is an important risk factor for calcium nephrolithiasis. This study evaluate the preventive effects of potassium sodium citrate on stone recurrence as well as stone growth post ESWL or PCNL, in patients with calcium-containing stones.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
- age > 18 years
- stone free or had residual calcium oxalate stone fragments with a less than 4 mm. diameter at eight weeks after ESWL or PCNL
- renal tubular obstruction
- serum creatinine > 2 mg/dl
- urinary tract infection (bacteria > 100,000 in urine culture)
- hypersensitive or contraindication to Potassium sodium hydrogen citrate
- insertion Double-J Stent
- history of arrhythmia, myocardial infarction or digitalis administration
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method rate of stone recurrence or stone growth 12 months The patients were evaluated at 6 months after the initial treatment for serum chemistry and urinalysis. After 12 months, all patients were evaluated for serum chemistry, urinalysis, 24-hour urine study and plain KUB.
- Secondary Outcome Measures
Name Time Method